INNOVIVA, INC. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
INNOVIVA, INC. (INVA) had Fair Value, Assets, Level 1 to Level 2 Transfers, Amount of $10.10 million as of 2013-03-31, per its 10-Q filed 2013-05-01.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount · last filed 2014-03-03
- 2013-03-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $10.10M.
- 2012-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2012-09-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $5.00M.
- 2011-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $5.00M.
| Period end | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2013-03-31 | $10.10M 10-Q · filed 2013-05-01 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-03 |
| 2012-09-30 | $5.00M 10-Q · filed 2012-10-31 |
| 2011-12-31 | $5.00M 10-Q · filed 2012-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |